An observational study in Antiphospholipid Syndrome, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to female participants. Per ClinicalTrials.gov, last updated 2022-08-08.
Sponsored by Imperial College London · Observational
This study is being done to see if there are any long term health related issues in women with APA and recurrent miscarriages.
The association between APA and thrombosis is well documented. Both LA and ACA are often detected in individuals with SLE but there is no prospective data on the risk of thrombosis in women who present with recurrent miscarriages in association with APA. This study should significantly advance medical knowledge of the natural history of primary antiphospholipid syndrome (PAPS) which is essential to enable optimal management of relatively young women who may be at risk of complications, some of which are potentially life threatening.
121 studies on the registry are indexed under Antiphospholipid Syndrome; 51 are open to participants now.
This study's planned enrollment of 250 is above the median of 181 across 52 observational studies indexed under Antiphospholipid Syndrome.
Browse Antiphospholipid Syndrome studies →Imperial College London is the lead sponsor of 824 studies on the registry; 178 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Antiphospholipid syndrome History of recurrent miscarriages
Exclusion Criteria:
Previous thromboembolic disease
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imperial College London